Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Nevada Ebglyss Coverage Update | OpenPaye…
    Ask Trek AI about this page
    ModifiedAmbetter NevadaPolicy CP.PCH.58

    Clinical Policy: Lebrikizumab-lbkz (Ebglyss)

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.PCH.58 alerts

    Get alerted when Policy CP.PCH.58 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs commercial and HIM/ICHRA prior authorization coverage for Ebglyss used to treat moderate-to-severe atopic dermatitis in eligible members. It defines initial and continued-therapy criteria, dosing limits, documentation requirements, exclusions, and referral rules for other uses.

    Policy Summary
    PayerAmbetter Nevada
    PolicyLebrikizumab-lbkz (Ebglyss) coverage
    Policy CodePolicy CP.PCH.58
    Change TypeModified
    Effective DateDec 1, 2025
    Last ReviewNov 1, 2026
    Next Review DateNot specified
    Key ActionSubmit documentation confirming that the member meets all applicable initial or continued-therapy approval criteria, including required treatment failures and dosing limits.
    SourceLink
    POLICY UPDATE CHANGES

    The 4Q 2026 annual review added every-8-week maintenance dosing as an option for initial and continued therapy in accordance with the prescribing information.

    The 4Q 2026 annual review added Nemluvio as an example of a biologic medication for which concurrent use is excluded.

    The original policy added redirection to preferred agents Dupixent or Rinvoq in the atopic dermatitis initial approval criteria.

    ≥12 yearsMinimum age
    ≥40 kgMinimum weight
    ≥10% BSA

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Disease extent
    Q4 or Q8 weeksMaintenance dosing
    6 monthsCommercial approval

    Coverage Criteria

    Initial Therapy — Atopic Dermatitis

    Covered for initial therapy when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of atopic dermatitis affecting at least one of the following: (a) at least 10% of the member's body surface area (BSA); or (b) the hands, feet, face, neck, scalp, genitals/groin, and/or intertriginous areas.
    • Prescribed by or in consultation with a dermatologist or allergist.
    • Member is age ≥ 12 years.
    • Member weighs ≥ 40 kg.
    • ONE of the following, unless contraindicated or clinically significant adverse effects are experienced:

      • ALL of the following

        • Failure of two formulary medium- to very-high-potency topical corticosteroids of different molecular identities, each used for ≥ 2 weeks.
        • Failure of one non-steroidal topical therapy used for ≥ 4 weeks: a topical calcineurin inhibitor (e.g., tacrolimus 0.03% ointment or pimecrolimus 1% cream) or Eucrisa®.

          These agents may require prior authorization.

      • For Illinois HIM requests only: failure of one topical therapy.
    • Failure of Dupixent® or Rinvoq®, used for ≥ 4 consecutive months, unless clinically significant adverse effects are experienced or both are contraindicated.

      For Illinois HIM requests, the step-therapy requirements above do not apply as of 1/1/2026 per IL HB 5395.

    • Ebglyss is not prescribed concurrently with another biologic immunomodulator (e.g., Dupixent, Adbry®, Nemluvio®, Cinqair®, Fasenra®, Nucala®, Tezspire®, or Xolair®) or a JAK inhibitor (e.g., Olumiant®, Rinvoq, Cibinqo®, or Opzelura®).
    • Dose does not exceed one of the following:

      • Loading dose: 500 mg (two 250 mg/2 mL injections) at Week 0 and Week 2.
      • Initial dose: 250 mg injection every 2 weeks until Week 16 or clinical response.
      • Maintenance dose: 250 mg every 4 weeks or every 8 weeks.

    Continuation Therapy — Atopic Dermatitis

    Covered for continuation therapy when ALL of the following criteria are met:

    ALL of the following

    • ONE of the following:

      • Member is currently receiving Ebglyss through a Centene benefit or has previously met the initial approval criteria.
      • Member is currently receiving Ebglyss and is enrolled in a state and product with continuity-of-care regulations; refer to state-specific addendums CC.PHARM.03A and CC.PHARM.03B.
    • Member is responding positively to therapy, as evidenced by, including but not limited to, reduction in itching or scratching.
    • Ebglyss is not prescribed concurrently with another biologic immunomodulator (e.g., Dupixent, Adbry, Nemluvio, Cinqair, Fasenra, Nucala, Tezspire, or Xolair) or a JAK inhibitor (e.g., Olumiant, Rinvoq, Cibinqo, or Opzelura).

    Other Diagnoses or Indications

    Coverage for other diagnoses or indications follows ONE of the pathways below:

    ONE of the following:

    • If the drug has recently, within the last 6 months, undergone a label change (e.g., newly approved indication, age expansion, or new dosing regimen) that is not yet reflected in this policy, refer to the applicable policy based on formulary or PDL status: for drugs on the formulary or PDL, CP.CPA.190 for commercial or HIM.PA.33 for health insurance marketplace/ICHRA; for drugs not on the formulary or PDL, CP.CPA.190 for commercial or HIM.PA.103 for health insurance marketplace/ICHRA.
    • If the requested use (e.g., diagnosis, age, or dosing regimen) is not specifically listed under Section III (Diagnoses/Indications for which coverage is NOT authorized), and the label-change criterion above does not apply, refer to the off-label use policy: CP.CPA.09 for commercial or HIM.PA.154 for health insurance marketplace/ICHRA.

    Coverage is not authorized for non-FDA-approved indications that are not addressed in this policy unless there is sufficient documentation of efficacy and safety according to the applicable off-label use policy (CP.CPA.09 for commercial or HIM.PA.154 for health insurance marketplace/ICHRA) or evidence of coverage documents.

    Ebglyss must not be prescribed concurrently with another biologic immunomodulator or a Janus kinase (JAK) inhibitor. Biologic examples include Dupixent, Adbry, Nemluvio, Cinqair, Fasenra, Nucala, Tezspire, and Xolair; JAK inhibitor examples include Olumiant, Rinvoq, Cibinqo, and Opzelura.

    Ebglyss is contraindicated in members with a prior serious hypersensitivity reaction to Ebglyss.

    Ebglyss is contraindicated in members with a prior serious hypersensitivity to lebrikizumab-lbkz or any excipient of Ebglyss.

    Concurrent use of Ebglyss with another biologic immunomodulator is excluded, including Nemluvio as an example of a biologic medication that must not be used concurrently.

    Coding

    HCPCS CodesHCPCS
    J3590Unclassified biologics
    C9399Unclassified drugs or biologicals

    Provider Actions

    Prior Authorization

    Initial Prior Authorization

    Submit an initial prior authorization request with documentation demonstrating that the member meets all applicable atopic dermatitis approval criteria for Ebglyss.

    • Diagnosis and qualifying disease involvement
    • Prescriber or consultation by a dermatologist or allergist
    • Age and weight requirements
    • Required topical and systemic therapy failures
    • Nonconcurrent therapy and policy-compliant dosing
    Prior Authorization

    Continuation Prior Authorization

    Continuation prior authorization requests must document current Ebglyss coverage or prior approval and a positive clinical response to therapy.

    • Current medication coverage through the Centene benefit, prior satisfaction of initial criteria, or applicable continuity-of-care eligibility

    Background

    Lebrikizumab-lbkz (Ebglyss) is an interleukin-13 antagonist indicated by the FDA for adults and pediatric patients 12 years of age and older who weigh at least 40 kg and have moderate-to-severe atopic dermatitis that is not adequately controlled with topical prescription therapies or when topical therapies are not advisable. Ebglyss may be used with or without topical corticosteroids.

    Definitions

    Definitions
    AbbreviationFDA
    Full nameFood and Drug Administration
    Policy referenceFDA-approved indications
    Definitions
    AbbreviationJAK
    Full nameJanus kinase
    Policy referenceJAK inhibitor

    Initial Therapy Criteria

    Ebglyss Initial Therapy

    Initial Ebglyss therapy is covered for qualifying atopic dermatitis when ALL of the following are met:

    Ebglyss initial therapy

    • Qualifying disease extent

      • Atopic dermatitis affects at least 10% of the member's BSA.≥10% BSA
      • Atopic dermatitis affects the hands, feet, face, neck, scalp, genitals/groin, and/or intertriginous areas.
    • Ebglyss is prescribed by or in consultation with a dermatologist or allergist.
    • Member is at least 12 years old and weighs at least 40 kg.

    Continuation Therapy Criteria

    Ebglyss Continuation Therapy

    Ebglyss continuation therapy is covered when ALL of the following are met:

    Ebglyss continuation criteria

    • Eligibility for continuation

      • Member is currently receiving Ebglyss through the Centene benefit.
      • Member previously met the initial approval criteria.
      • Member is currently receiving Ebglyss and is enrolled in a state and product with continuity-of-care regulations.

        Refer to the applicable state-specific continuity-of-care addendum.

    • Member is responding positively to therapy, including reduction in itching or scratching.

    Step Therapy Requirements

    StepRequirementDetails
    1Topical therapy failureFail two formulary medium- to very-high-potency topical corticosteroids of different molecular identities, each used for at least 2 weeks, plus one nonsteroidal topical therapy used for at least 4 weeks. Nonsteroidal options include a topical calcineurin inhibitor or Eucrisa. Exceptions apply for contraindication or clinically significant adverse effects.
    StepRequirementDetails
    2Systemic therapy failureFail Dupixent or Rinvoq used for at least 4 consecutive months, unless clinically significant adverse effects occur or both therapies are contraindicated.
    StepRequirementDetails
    1Preferred-agent redirectionFor initial atopic dermatitis approval, redirect to the preferred agents Dupixent or Rinvoq.

    Quantity and Dosing Limits

    Quantity Limits
    ProductEbglyss
    Loading dose500 mg
    AdministrationTwo 250 mg/2 mL injections at Week 0 and Week 2
    Quantity Limits
    ProductEbglyss
    Initial dose250 mg injection every 2 weeks
    DurationUntil Week 16 or clinical response
    Policy Summary
    PayerAmbetter Nevada
    PolicyLebrikizumab-lbkz (Ebglyss) coverage
    Policy CodePolicy CP.PCH.58
    Change TypeModified
    Effective DateDec 1, 2025
    Last ReviewNov 1, 2026
    Next Review DateNot specified
    Key ActionSubmit documentation confirming that the member meets all applicable initial or continued-therapy approval criteria, including required treatment failures and dosing limits.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider ActionsBackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaStep Therapy RequirementsQuantity and Dosing Limits

    Dose does not exceed one of the following maintenance regimens:

    • 250 mg injection every 4 weeks.
    • 250 mg injection every 8 weeks.
  1. Positive response, such as reduced itching or scratching
  2. No prohibited concurrent therapy
  3. Maintenance dosing does not exceed 250 mg every 4 or 8 weeks
  4. Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Ebglyss initial and continued therapy. Initial requests are subject to the policy criteria and preferred-agent redirection to Dupixent or Rinvoq.

    • Apply initial-therapy criteria before requesting Ebglyss
    • Document continuation eligibility and response for renewals
    • Redirect initial approval requests to Dupixent or Rinvoq when applicable
    Denial Risk

    Failure to Meet Initial Clinical Criteria

    Initial approval may be denied when the member does not meet the required diagnosis, disease involvement, age, weight, or prescriber criteria.

    • Atopic dermatitis must affect at least 10% of body surface area or involve the hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas
    • Member must be at least 12 years old
    • Member must weigh at least 40 kg
    • Prescription must be from or in consultation with a dermatologist or allergist
    Denial Risk

    Concurrent Therapy or Excessive Dosing

    Ebglyss must not be prescribed concurrently with another biologic immunomodulator or a JAK inhibitor, and dosing must remain within the policy limits.

    • Do not use concurrently with biologics such as Dupixent, Adbry, Nemluvio, Cinqair, Fasenra, Nucala, Tezspire, or Xolair
    • Do not use concurrently with JAK inhibitors such as Olumiant, Rinvoq, Cibinqo, or Opzelura
    • Loading dose: 500 mg at Week 0 and Week 2
    • Initial dose: 250 mg every 2 weeks until Week 16 or clinical response
    • Maintenance dose: 250 mg every 4 weeks or every 8 weeks
    Denial Risk

    Prior Serious Hypersensitivity

    Coverage is contraindicated and may be denied when the member has a prior serious hypersensitivity to lebrikizumab-lbkz or any Ebglyss excipient.

    • Review the member's allergy and hypersensitivity history before prescribing
    Documentation Required

    Clinical Documentation

    Submit office chart notes, laboratory results, or other clinical information supporting that the member meets all applicable approval criteria.

    • Clinical documentation must support the diagnosis, treatment history, response, safety, and dosing requested
    Documentation Required

    Initial-Therapy Supporting Records

    Initial-therapy requests must include records supporting the diagnosis, qualifying disease involvement, age, weight, and prescriber qualifications.

    • Document at least 10% BSA involvement or qualifying involvement of the hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas
    • Include member age and weight
    • Identify the dermatologist or allergist prescribing or providing consultation
    • Document failure, contraindication, or clinically significant adverse effects for required topical and systemic therapies
    Documentation Required

    Continuation-Therapy Supporting Records

    Continuation requests must include evidence of prior approval or continuity eligibility and documentation that the member is responding positively to Ebglyss.

    • Document current Centene-benefit coverage, prior satisfaction of initial criteria, or applicable state and product continuity-of-care eligibility
    • Document positive clinical response, including reduced itching or scratching
    • Confirm requested maintenance dose and absence of prohibited concurrent therapy
    Denial Risk

    Failure to Meet Initial Clinical Criteria

    Initial approval may be denied when required clinical criteria are not met, including the qualifying diagnosis or disease involvement, minimum age, minimum weight, or appropriate prescriber qualification.

    • Atopic dermatitis must meet the required BSA or specified body-location criterion
    • Member must be at least 12 years old and weigh at least 40 kg
    • Prescription must be by or in consultation with a dermatologist or allergist
    Denial Risk

    Concurrent Therapy or Excessive Dosing

    Coverage may be denied for prohibited concurrent treatment or dosing that exceeds the approved loading, initial, or maintenance limits.

    • No concurrent biologic immunomodulator, including Nemluvio, or JAK inhibitor
    • Loading dose may not exceed 500 mg at Week 0 and Week 2
    • Maintenance dose may not exceed 250 mg every 4 weeks or every 8 weeks
    Denial Risk

    Uncovered Indication

    Coverage is not authorized for non-FDA-approved indications unless sufficient efficacy and safety documentation supports the use under the applicable off-label policy or evidence of coverage documents.

    • Reference CP.CPA.09 for commercial, HIM.PA.154 for marketplace/ICHRA, or applicable evidence of coverage documents
    Denial Risk

    Prior Serious Hypersensitivity

    Ebglyss is contraindicated for members with prior serious hypersensitivity to lebrikizumab-lbkz or any excipients of Ebglyss.

    • Do not approve or administer when this contraindication is present
    Denial Risk

    Concurrent Biologic Therapy

    Ebglyss must not be used concurrently with another biologic immunomodulator, including Nemluvio, or with a JAK inhibitor.

    • Review the complete medication profile before initial approval and continuation
    • Concurrent examples include Dupixent, Adbry, Nemluvio, Cinqair, Fasenra, Nucala, Tezspire, Xolair, Olumiant, Rinvoq, Cibinqo, and Opzelura
    Definitions
    AbbreviationBSA
    Full nameBody surface area
    Atopic dermatitis criterionAt least 10% of the member's body surface area, or specified sensitive areas
    Age ≥12 years; weight ≥40 kg
  5. Required treatment history

    • Member has failed two formulary medium- to very-high-potency topical corticosteroids of different molecular identities, each used for at least 2 weeks, and one nonsteroidal topical therapy used for at least 4 weeks.≥2 weeks for each corticosteroid; ≥4 weeks for the nonsteroidal topical

      Nonsteroidal options include a topical calcineurin inhibitor or Eucrisa.

    • The required topical therapy was contraindicated or caused clinically significant adverse effects.
  6. Required systemic therapy history

    • Member has failed Dupixent or Rinvoq used for at least 4 consecutive months.≥4 consecutive months
    • Member experienced clinically significant adverse effects from Dupixent or Rinvoq.
    • Both Dupixent and Rinvoq are contraindicated.
  7. Concurrent therapy and dosing

    • Ebglyss is not prescribed concurrently with another biologic immunomodulator or JAK inhibitor.
    • Dose does not exceed policy limits

      • Loading dose is 500 mg, given as two 250 mg/2 mL injections at Week 0 and Week 2.
      • Initial dose is 250 mg by injection every 2 weeks until Week 16 or clinical response.
      • Maintenance dose is 250 mg every 4 weeks or every 8 weeks.250 mg every 4 or 8 weeks
  8. Ebglyss is not prescribed concurrently with another biologic immunomodulator or JAK inhibitor.
  9. Dose does not exceed 250 mg by injection every 4 weeks or every 8 weeks.250 mg every 4 or 8 weeks
  10. Quantity Limits
    ProductEbglyss
    Maintenance dose250 mg
    FrequencyEvery 4 weeks or every 8 weeks